{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:51:54Z","timestamp":1790373114307,"version":"4.1.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint molecules represent physiological brakes of the immune system that are essential for the maintenance of immune homeostasis and prevention of autoimmunity. By inhibiting these negative regulators of the immune response, immune checkpoint blockade can increase anti-tumor immunity, but has been primarily successful in solid cancer therapy and Hodgkin lymphoma so far. Allogeneic hematopoietic cell transplantation (allo-HCT) is a well-established cellular immunotherapy option with the potential to cure hematological cancers, but relapse remains a major obstacle. Relapse after allo-HCT is mainly thought to be attributable to loss of the graft-versus-leukemia (GVL) effect and hence escape of tumor cells from the allogeneic immune response. One potential mechanism of immune escape from the GVL effect is the inhibition of allogeneic T cells via engagement of inhibitory receptors on their surface including PD-1, CTLA-4, TIM3, and others. This review provides an overview of current evidence for a role of immune checkpoint molecules for relapse and its treatment after allo-HCT, as well as discussion of the immune mediated side effect graft-vs.-host disease. We discuss the expression of different immune checkpoint molecules on leukemia cells and T cells in patients undergoing allo-HCT. Furthermore, we review mechanistic insights gained from preclinical studies and summarize clinical trials assessing immune checkpoint blockade for relapse after allo-HCT.<\/jats:p>","DOI":"10.3389\/fimmu.2021.634435","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T04:53:04Z","timestamp":1614919984000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Natalie","family":"K\u00f6hler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich Alexander","family":"Ruess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kesselring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the united states","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol. Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies","volume":"54","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","article-title":"Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"54","author":"Lee","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.bloodjournal76122462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature Rev. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1074-7613(00)00031-5","article-title":"The CD28 and CTLA-4 receptors associate with the serine\/threonine phosphatase PP2A","volume":"13","author":"Chuang","year":"2000","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ni1144","article-title":"B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator","volume":"6","author":"Sedy","year":"2005","journal-title":"Nat. Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.bbrc.2003.11.070","article-title":"Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2","volume":"312","author":"Gavrieli","year":"2003","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J. Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","article-title":"Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion","volume":"18","author":"Rangachari","year":"2012","journal-title":"Nat. Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J. Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00520-017-3802-9","article-title":"Supportive care for patients undergoing immunotherapy","volume":"25","author":"Rapoport","year":"2017","journal-title":"Support. Care Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-11-0108","article-title":"PD-1\/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation","volume":"71","author":"Norde","year":"2011","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbmt.2018.09.037","article-title":"Over-expression of PD-1 does not predict leukemic relapse after allogeneic stem cell transplantation","volume":"25","author":"Jain","year":"2019","journal-title":"Biol. Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat. Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbmt.2017.11.027","article-title":"Increased coexpression of PD-1, TIGIT, and KLRG-1 on tumor-reactive CD8(+) T cells during relapse after allogeneic stem cell transplantation","volume":"24","author":"Hutten","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B42","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1182\/blood-2019-127779","article-title":"Evaluation of TIM-3-positive LSCs post allo-SCT is a highly sensitive strategy to predict AML relapses","volume":"134","author":"Sakoda","year":"2019","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"B46","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.4049\/jimmunol.162.11.6368","article-title":"Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells","volume":"162","author":"Blazar","year":"1999","journal-title":"J. Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J. Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1172\/JCI39165","article-title":"Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice","volume":"120","author":"Asakura","year":"2010","journal-title":"J. Clin. Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1172\/JCI41446","article-title":"Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation","volume":"120","author":"Flutter","year":"2010","journal-title":"J. Clin. Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood-2010-04-283119","article-title":"PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells","volume":"117","author":"Koestner","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.immuni.2015.12.008","article-title":"The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation","volume":"44","author":"Michonneau","year":"2016","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1172\/JCI85796","article-title":"Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality","volume":"126","author":"Saha","year":"2016","journal-title":"J. Clin. Invest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41467-020-17991-y","article-title":"T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1182\/blood-2011-07-367011","article-title":"Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41590-019-0403-4","article-title":"Single-cell RNA-seq reveals TOX as a key regulator of CD8(+) T cell persistence in chronic infection","volume":"20","author":"Yao","year":"2019","journal-title":"Nat. Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood.V130.Suppl_1.275.275","article-title":"Optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-17-2777","article-title":"Ipilimumab plus Lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies","volume":"24","author":"Khouri","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41409-019-0498-0","article-title":"The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma","volume":"54","author":"Holderried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2018-99-115108","article-title":"Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic cell transplantation","volume":"132","author":"Kline","year":"2018","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bbmt.2010.08.005","article-title":"CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells","volume":"17","author":"Zhou","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B73","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/bmt.2015.346","article-title":"Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e26257","DOI":"10.1002\/pbc.26257","article-title":"Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report","volume":"64","author":"Shad","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","article-title":"Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma","volume":"52","author":"El Cheikh","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/bmt.2017.107","article-title":"MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD","volume":"52","author":"Boekstegers","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2787","article-title":"Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting","author":"Chan","year":"2020","journal-title":"Hematol. Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.bbmt.2020.01.021","article-title":"Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/sji.12597","article-title":"Systemic treatment with a miR-146a mimic suppresses endotoxin sensitivity and partially protects mice from the progression of acute graft-versus-host disease","volume":"86","author":"Gartner","year":"2017","journal-title":"Scand. J. Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1038\/leu.2017.137","article-title":"MicroRNA-146a reduces MHC-II expression via targeting JAK\/STAT signaling in dendritic cells after stem cell transplantation","volume":"31","author":"Stickel","year":"2017","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2014-04-569046","article-title":"MiR-146a regulates the TRAF6\/TNF-axis in donor T cells during GVHD","volume":"124","author":"Stickel","year":"2014","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e132334","DOI":"10.1172\/jci.insight.132334","article-title":"MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors","volume":"5","author":"Marschner","year":"2020","journal-title":"JCI Insight"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.634435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T12:04:07Z","timestamp":1697976247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.634435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2021.634435"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.634435","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"article-number":"634435"}}